Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and radiation for pediatric DIPG
NCT01189266Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2010
- Primary completion
- Jun 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of vorinostat in diffuse intrinsic pontine glioma (DIPG), sponsored by National Cancer Institute. Started Aug 2010; status: completed.
02
Drugs
vorinostat
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT01189266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189266.